Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
- Written by PR Newswire
 |
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases
SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) CEO Dr Steven...
